Breaking News, Collaborations & Alliances

Dr. Reddy’s, Coya Therapeutics Partner on ALS Therapy

Dr. Reddy’s will pay $7.5 million upfront and an additional $4.2 million upon the first FDA acceptance of an IND.

Dr. Reddy’s Laboratories has entered into a development and license agreement with Coya Therapeutics, Inc. for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the U.S., Canada, the EU, and the United Kingdom. The agreement is in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters